[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammation-biomarkers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammation-biomarkers":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,54,86,127,155,197,223,241,288,322,349,381,418,450,474,507,540,564],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100623383","resveratrol-effects-on-inflammatory-biomarkers-and-cardiometabolic-parameters-100623383",false,"NCT07395921","Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.","Effects of Resveratrol Supplementation on Inflammatory Biomarkers and Cardiometabolic Parameters in Community-dwelling Adults. (RESINCA-trial)","RESINCA","Inclusion Criteria:\n\n* Comunnity-dwelling persons.\n* Any ethnicity.\n* With willingness to consume the bar daily during the intervention period.\n\nExclusion Criteria:\n\n* Allergy\u002Fintolerance to ingredients in the bar.\n* Pregnancy or breastfeeding.\n* Use of antioxidant\u002Fpolymeroid supplements in the last 4 weeks.\n* Unstable chronic diseases (e.g., severe liver failure, advanced kidney failure, active cancer).\n* Persons in treatments that strongly interfere with polyphenol metabolism (e.g., antibiotics, anti-inflammatories, corticosteroids, anti-allergy medication).\n* Persons with metal prosthesis.\n* Persons undergoing or waiting for metabolic bariatric surgery.\n* Persons with scheduled digestive surgery within the next 8 weeks\n* Persons in recent treatments for hypertension (less than 3 month).\n* Participation in another clinical trial.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},75,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers and cardiometabolic parameters in community-dwelling adults",[29,30,31,32,33],"Inflammation Biomarkers","Cardiometabolic Health Indicators","Antioxidant Status, Inflammation","Antioxidant Capabilities","Inflammaging",[35,36,37,38,39,40],"Resveratrol","inflammation","inflammaging","antioxidant","cardiometabolic health","nutritional intervention","NOT_YET_RECRUITING","2026-05-18",{"date":44,"type":45},"2026-05-19","ACTUAL",{"date":47,"type":23},"2026-06-01",{"date":49,"type":23},"2026-12-01",{"name":51,"class":52},"Center for Research and Innovation Viña Concha y Toro","INDUSTRY",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100612884","neuro-inflammation-in-extremity-trauma-risk-verification-in-elbow-trauma-the-nerve-study-100612884","NCT07259382","Neuro-Inflammation in Extremity Trauma: Risk Verification in Elbow Trauma: The NERVE Study","Neuro-Inflammation in Extremity Trauma: Risk Verification in Elbow Trauma: The NERVE Pilot Cohort Study","NERVE","Inclusion Criteria:\n\n* Adults 18 years or older with an acute elbow fracture and\u002For dislocation less than a week old\n* Open surgery as the chosen treatment\n\nExclusion Criteria:\n\n* Patient with a history of ipsilateral upper limb trauma or pathology, neurological disorder.\n* Patient unable to answer questionnaires.\n* Patient unavailable for a one-year follow-up, for example from another country.\n* Patient with vascular injury or open fracture\n* Patient with an active inflammatory disease (ex: rheumatoid arthritis)\n* Patient using anti-inflammatory drugs or immunosuppressants at the time of the injury.\n* Patient with another acute ipsilateral injury to the upper limb\n* Polytrauma patients with other injuries than the elbow fracture and concomitant central or peripheral neurological injury.",{"count":63,"type":23},60,"OBSERVATIONAL","The primary goal of this proposal is to improve the understanding of the mechanisms causing persistent pain and disability in elbow fracture patients and their associated functional limitations. The specific objectives are as follows for elbow fractures:\n\n1\\) To describe NI mechanisms using biomarkers; 2) To identify factors related to increased NI biomarkers level; 3) To describe the associations between NI and outcomes; 4) To use these findings to refine a larger fully powered prognostic cohort study Hypotheses\n\n1. Level of neuro-inflammation (NI) biomarkers\\* will be significantly higher in patients presenting with both elbow fracture and CNS injury or PNI.\n2. Consumption of opioid in mg of morphine equivalent will be higher in patients with a higher level of NI biomarkers.\n3. Function, assessed by validated joint and limb specific functional questionnaires and QoL will be worse in patients with a higher level of NI biomarkers.\n4. Chronic pain at 3 months will be higher (McGill Pain questionnaire V2, Neuropathic pain questionnaire, NPRS) in patients with a higher level of NI biomarkers.\n5. Duration of tourniquet use and nerve dissection will be correlated to elbow fracture outcome with a higher level of NI biomarkers.\n\n   * Target biomarkers based on preliminary study will include, but not be limited to: TNFa, IL6, Substance P, IL-1B, TREM-2, IL-16, CCL22, VEGF-a, BMPs (table 1).",[67,68,29,69,70],"Elbow Dislocation","Elbow Fractures","TBI Traumatic Brain Injury","Nerve Injury",[72,73,74,75,76],"Biomarkers","Elbow fracture","elbow dislocation","Nerve injury","TBI","2026-04-27",{"date":79,"type":45},"2026-04-28",{"date":47,"type":23},{"date":82,"type":23},"2030-12-31",{"name":84,"class":85},"Université de Montréal","OTHER",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":17,"sex":18,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":53},"100635233","effects-of-dietary-fats-on-gut-microbiota-composition-and-metabolic-activity-in-healthy-adults-100635233","NCT07550023","Effects Of Dietary Fats on Gut Microbiota Composition and Metabolic Activity in Healthy Adults","Inclusion Criteria:\n\n* Adults aged 20-50 years\n* Body mass index (BMI) between 20 and 30 kg\u002Fm²\n* Generally healthy\n* Stable body weight (±2 kg) over the past 2 months\n* Living in the Glasgow area\n* Non-smoker\n\nExclusion Criteria:\n\n* Use of antibiotics within the past 3 months\n* Current use of medications affecting gut microbiota or cardiometabolic health\n* Regular use of dietary supplements that may influence study outcomes (e.g. probiotics, prebiotics, vitamins, minerals, fish oil), unless willing to discontinue prior to study start\n* Presence of chronic gastrointestinal, metabolic, cardiovascular, hepatobiliary, or pancreatic disease\n* History of major gastrointestinal surgery\n* Diagnosed diabetes or use of lipid-lowering therapy\n* Known fat malabsorption disorders\n* Pregnant or lactating women\n* Post-menopausal women\n* Following a restrictive or specific diet (e.g. vegan, ketogenic diet)\n* Food allergies or intolerances relevant to study interventions (e.g. dairy, coconut)\n* Recent significant weight change (±2 kg in the past month)\n* High reliance on ready meals or takeaway foods (\\>7 main meals per week)\n* Participation in another research study that may interfere with this study","20 Years","50 Years",{"count":95,"type":23},64,[26],"This study will investigate how adding a specific type of dietary fat to daily meals for two weeks affects the gut bacteria and their activity. Participants will be randomly assigned to consume one of four types of fat: butter, coconut oil, olive oil, or sunflower oil (60 mL each day for 2 weeks). Stool and blood samples (after an overnight fast) will be collected at 3 time points during the study (Days 1, 7, and 22). These samples will be used to measure metabolites produced by gut bacteria, the types of bacteria present in the gut, blood lipids, and inflammatory markers. The study, based on previous in vitro findings, aims to understand whether different types of fats (based on their structure and level of saturation) have different effects on gut bacteria and their activity in healthy subjects.",[99,100,101,29],"Short Chain Fatty Acids Concentration in Stools","Gut Microbiota Diversity and Composition","Blood Lipid Profiles",[103,104,105,106,107,108,109,110,111,112,113,114,115,116],"Gut microbiome","Gut microbiota","Dietary fat","Short-chain fatty acids","SCFA","Saturated fat","Monounsaturated fat","Polyunsaturated fat","Butter","Olive oil","Coconut oil","Sunflower oil","MUFA","PUFA","RECRUITING","2026-04-17",{"date":120,"type":45},"2026-04-24",{"date":122,"type":45},"2026-03-23",{"date":124,"type":23},"2028-03-31",{"name":126,"class":85},"University of Glasgow",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":53},"100626411","analysis-of-inflammatory-biomarker-changes-in-dry-blood-spot-versus-venous-blood-samples-100626411","NCT07435285","Analysis of Inflammatory Biomarker Changes in Dry Blood Spot Versus Venous Blood Samples","DBS-VB","Inclusion Criteria:\n\n* Men or women aged ≥18 years, who are planning to receive a seasonal vaccine OR have a scheduled acute stressor\\*.\n\nExclusion Criteria:\n\n* Any infectious symptoms (fever, cough, rhinorrhea, sore throat, diarrhea, loss of smell or taste) within the previous 7 days\n* Any self-reported active\u002Frecent use of cocaine, injection drugs, or amphetamines\n* Acute worsening of a known chronic health condition within the previous 30 days (e.g., of IBD, COPD, asthma, rheumatologic disease)\n* Known severe allergy or intolerance to the planned vaccine\n* Contraindication to the vaccine received, if applicable\n\n  \\*List of possible scheduled acute stressors include:\n* Hard exercise (incl. 10km run or longer, high-intensity interval training, or comparable endurance activity)\n* Social event with moderate alcohol consumption\n* Planned change in medication dose and\u002For frequency of use\n* Onset of menstruation (day 1)\n* Other pre-planned stressors expected to elicit an inflammatory response",{"count":135,"type":23},50,"The purpose of this study is to see whether dried blood spot (DBS) samples can measure inflammatory biomarkers as accurately as venous blood samples.\n\nInvestigators will be measuring inflammatory biomarkers changes obtained in DBS compared with paired venous blood samples following a controlled physiological stressor (i.e. after a vaccine or other planned event that can cause a temporary rise in inflammation).\n\nThese findings will help understand whether DBS can be a reliable alternative to traditional blood draws in future research and healthcare.",[138,29,139,140],"Inflammation","Blood Sampling","Dried Blood Spot",[36,142,143,144,145,146],"blood sampling","biomarkers","inflammatory biomarkers","dried blood spot","paired sampling",{"date":148,"type":45},"2026-03-27",{"date":150,"type":45},"2026-01-15",{"date":152,"type":23},"2026-12",{"name":154,"class":85},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":17,"sex":18,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":167,"conditions":168,"keywords":180,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":53},"100629594","expanded-studies-on-the-scapis-stockholm-reexamination-cohort-100629594","NCT07476703","Expanded Studies on the SCAPIS Stockholm Reexamination Cohort","Expanded Studies of Risk Factors for Pulmonary-, Liver-, and Cardiovascular Disease in the SCAPIS 2 Stockholm Reexamination","SCAPIS-ReEx","Inclusion Criteria: Subjects already included in the main \u002F general SCAPIS reexamination study in Stockholm.\n\nExclusion Criteria: Inability to provide consent.","56 Years","74 Years",{"count":166,"type":23},1400,"The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. The study is a collaborative effort among six university hospitals across Sweden. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet.\n\nSCAPIS 2 includes a core set of examinations involving blood sampling, questionnaires, and imaging. In addition to these, complementary local investigations are conducted to enable more detailed research questions. This protocol describes the additional studies conducted in the Stockholm cohort. All complementary assessments aim to identify risk factors for current and future lung, liver, and cardiovascular diseases.:\n\nEXTENDED SAMPLING: Saliva and Blood Samples with Blood Cell Isolation. EXTENDED QUESTIONNAIRES: Dyspnea, Sleep, Respiratory Infections, and Dental Health.\n\nEXTENDED IMAGING AND PHYSIOLOGICAL MEASUREMENTS Cardiac Ultrasound and Abdominal Aortic Measurements. Liver Elastography. Vascular Stiffness by cuff-based pulse wave analysis and Photoplethysmography (PPG). Valvular and Vascular Calcification by CT imaging.",[169,170,171,172,173,174,175,29,176,177,178,179],"Coronary Artery Disease","Arterial Stiffness, Blood Pressure","AORTIC VALVE DISEASES","Mitral Valve Stenosis and\u002For Insufficiency","Heart Failure","Pulmonary Disease, Chronic Obstructive (COPD)","Steatohepatitis","Lipid Profile","Oral Microbiota","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Associated-dysfunction Steatohepatitis (MASH)",[181,182,183,184,36,185,186,187],"coronary artery disease","arterial stiffness","MASLD","COPD","dyslipidemia","aortic aneurysm","oral microbiota","2026-03-12",{"date":190,"type":45},"2026-03-17",{"date":192,"type":45},"2024-04-08",{"date":194,"type":23},"2026-08-30",{"name":196,"class":85},"Danderyd Hospital",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":18,"minAge":204,"maxAge":20,"enrollmentInfo":205,"targetDuration":4,"studyType":24,"phases":206,"briefSummary":207,"conditions":208,"keywords":211,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":53},"100626560","effect-of-ginger-capsules-on-inflammation-oxidative-stress-and-endothelial-function-100626560","NCT07437222","Effect of Ginger Capsules on Inflammation, Oxidative Stress, and Endothelial Function","Study of the Effect of Ginger Capsules on Markers of Inflammation, Oxidative Stress, and Endothelial Damage","Inclusion Criteria:\n\n* Male and female participants.\n* Age between 23 and 65 years.\n* Body mass index (BMI) \\> 27.5 kg\u002Fm².\n* Absence of diagnosed chronic diseases.\n* Not receiving pharmacological treatment or dietary supplementation on a regular basis.\n* Ability to understand the study procedures and willingness to comply with study requirements.\n\nExclusion Criteria:\n\n* Presence of acute or chronic diseases not specified in the inclusion criteria.\n* Ongoing chronic pharmacological treatment or active use of dietary supplements.\n* Major surgery within the previous three months.\n* Current smokers or recent former smokers (less than six months since cessation).\n* History of clinically relevant food allergies or eating disorders.\n* Concurrent participation in another clinical trial or research study.\n* Pregnancy or breastfeeding.\n* Following an active weight-loss diet.\n* Investigator's judgment of unsuitability for study participation.","23 Years",{"count":135,"type":23},[26],"Randomized, double-blind, parallel, placebo-controlled clinical trial designed and conducted to evaluate the effect of daily consumption of ginger, on parameters related to inflammation, oxidative stress, and endothelial damage in adults with excess adiposity.",[29,209,210],"Oxidative Stress","Cardiometabolic Risk Factors",[29,209,212,213],"Randomized Controlled Trial","Ginger","2026-03-05",{"date":216,"type":45},"2026-03-09",{"date":218,"type":45},"2026-03-02",{"date":220,"type":23},"2026-06",{"name":222,"class":85},"Ana Mª Garcia Munoz",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":18,"minAge":204,"maxAge":20,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":230,"briefSummary":207,"conditions":231,"keywords":232,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":53},"100626312","effect-of-a-ginger-based-beverage-on-inflammation-oxidative-stress-and-endothelial-function-100626312","NCT07433998","Effect of a Ginger-Based Beverage on Inflammation, Oxidative Stress, and Endothelial Function","Study of the Effect of a Ginger-based Functional Beverage on Markers of Inflammation, Oxidative Stress, and Endothelial Damage.",{"count":135,"type":23},[26],[29,209,210],[233,209,212,213],"inflammation Biomarkers",{"date":235,"type":45},"2026-03-04",{"date":237,"type":23},"2026-03",{"date":220,"type":23},{"name":240,"class":85},"Javier Marhuenda",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":17,"sex":249,"minAge":250,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":253,"conditions":254,"keywords":268,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100628121","breastmilk-and-the-link-to-overweightobesity-and-maternal-diet-in-the-mother-breastmilk-child-triad-100628121","NCT07457515","Breastmilk and the Link to Overweight\u002FObesity and Maternal Diet in the Mother-breastmilk-child Triad","Analysis of the Transmission of Overweight\u002FObesity in the Mother-breastmilk-child Triad in Relation to Maternal Cardiometabolic Status and Diet","BLOOM-Triad","Inclusion Criteria:\n\nfor mother:\n\n* at least 19 years,\n* plan of exclusively or predominantly breastfeeding for 6 months,\n* consent to a sampling of biological material and participate in all planned procedures (for both mother and infant),\n* willingness to finish the follow-up,\n* well-understanding of the Polish language (for non-Polish nationalities); for infants:\n* 1 month or less,\n* clinically healthy,\n* none or one formula feeding per day\n\nExclusion Criteria:\n\nfor mother:\n\n* type 1 or 2 diabetes diagnosed before pregnancy,\n* uncontrolled thyroid disease,\n* breastfeeding more than 1 child or being a milk donor,\n* tobacco\u002Falcohol use during pregnancy or currently,\n* inability to express a sufficient amount of milk; for infants:\n* congenital disease,\n* birth from a multiple pregnancy,\n* preterm birth (\\\u003C37 Hbd).","FEMALE","19 Years",{"count":252,"type":23},165,"The prospective 5-month follow-up study will involve 150 mother-infant dyads grouped based on maternal baseline BMI category (normal weight, overweight, obesity). The investigators plan 3 study visits (1, 3, and 6 months postpartum) with analysis the following parameters and outcomes:\n\n1. maternal anthropometry and body composition;\n2. maternal dietary intake and dietary patterns (with results of biomarker-based validation);\n3. maternal status of lipophilic antioxidants, selected vitamins, and fatty acids profile that may be related to adipose tissue metabolism, inflammation, and cardiometabolic status;\n4. maternal metabolomics, adipokines, insulin, selected biomarkers of inflammation, altered glucose metabolism, and oxidation;\n5. breastmilk composition assessed by systemic approach (macronutrients, fatty acids profile, lipophilic antioxidants, adipokines, hormones, immunological profile, and preliminary lipidomic analysis in part of the study group);\n6. infant growth trajectory, body composition, urine metabolomics, and biomarkers of oxidative stress.\n\nAdditionally, maternal and infant stool, buccal swabs, and human milk samples will be banked for further microbiome analysis studies.",[255,256,257,258,259,260,261,262,263,264,265,266,29,267],"Body Weight","Obesity & Overweight","Human Milk\u002FBreastfeeding","Body Composition","Maternal Cardiometabolic Health","Growth & Development","Metabolomic Profile","Infant Body Composition and Metabolism","Carotenoid Status","Fatty Acid Status","Immunologic Markers","Adipokines","Vitamin E",[269,270,271,272,266,273,274,275,138,276,277,278,279],"Lactation","Body composition","Infant development","Diet","Carotenoids","Fatty acids","Metabolomics","Oxidative stress","Overweight","Obesity","Tocopherols",{"date":216,"type":45},{"date":282,"type":23},"2026-02",{"date":284,"type":23},"2029-09",{"name":286,"class":85},"Warsaw University of Life Sciences",4,{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":296,"targetDuration":297,"studyType":64,"phases":4,"briefSummary":298,"conditions":299,"keywords":305,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":53},"100621576","macrophagemonocyte-driven-inflammation-and-anesthetic-sensitivity-in-aging-100621576","NCT07372417","Macrophage\u002FMonocyte Driven Inflammation and Anesthetic Sensitivity in Aging","Role of Macrophage\u002FMonocyte Mediated Inflammatory Response in Diminished Anesthetic Requirements During Aging","MACRO-AGE","Inclusion Criteria:\n\n* Age between 18-30 years or over 60 years old\n* Scheduled for abdominal surgery\n* General anesthesia planned with or without spinal anesthesia\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Chemotherapy or systemic corticosteroid use within the past 2 weeks.\n* Pregnancy.\n* Active sepsis or systemic infection.\n* Emergency surgery.\n* Requirement of ketamine or dexmedetomidine during the first hour of anesthesia.\n* History or diagnosis of: stroke with persistent neurological deficit, dementia, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, central nervous system autoimmune disorders, systemic autoimmune diseases, or infectious diseases of the central nervous system.\n* Current treatment with immunomodulatory medications.\n* Psychiatric disorders with psychotic features.\n* Use of psychoactive or psychotropic recreational drugs within the week prior to surgery.",{"count":63,"type":23},"1 Day","The goal of this observational study is to determine whether macrophage\u002Fmonocyte mediated inflammatory signaling contributes to reduced anesthetic requirements in older adults undergoing major abdominal surgery. The main questions it aims to answer are:\n\n* Is there a difference in anesthetic dosing requirements (minimum effective dose) between young and older patients undergoing major abdominal surgery?\n* How do electroencephalographic (EEG) signatures under anesthesia correlate with age and systemic inflammatory markers?\n* Is there an association between age, levels of circulating inflammatory cytokines, and monocyte\u002Fmacrophage phenotypes with anesthetic requirements?\n\nIf there is a comparison group: Researchers will compare older adult patients undergoing major abdominal surgery to younger adult patients undergoing major abdominal surgery to see if macrophage\u002Fmonocyte-mediated inflammatory signaling influences anesthetic sensitivity and the risk of postoperative neurocognitive complications in the older population.\n\nParticipants will:\n\n* Receive general anesthesia for major abdominal surgery, with continuous recording of anesthetic dose requirements.\n* Undergo electroencephalographic (EEG) monitoring during the anesthetic period.\n* Provide blood samples for the measurement of circulating inflammatory cytokines and the assessment of monocyte phenotypes.\n* Provide peritoneal tissue samples (collected during surgery) to evaluate tissue macrophage populations.\n* Provide cerebrospinal fluid (CSF) samples to assess biomarkers of blood-brain barrier permeability.",[300,138,301,302,303,29,33,304],"Aging","Blood-Brain Barrier Permeability","Anesthesia Brain Monitor","Anesthesia Depth Monitoring","Monocyte",[300,138,306,307,308,309,310,311,312],"General Anesthesia","Anesthetic Sensitivity","Cytokines","Alpha Oscillations","Blood Brain Barrier","Monocyte phenotype","macrophage phenotype","2026-01-19",{"date":315,"type":45},"2026-01-28",{"date":317,"type":23},"2026-01-25",{"date":319,"type":23},"2027-06-15",{"name":321,"class":85},"University of Chile",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":330,"targetDuration":332,"studyType":64,"phases":4,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":4},"100617545","descriptive-study-of-circulating-gene-or-protein-inflammatory-biomarkers-and-bioimpedance-parameters-in-a-population-of-patients-hospitalized-for-decompensated-heart-failure-with-preserved-or-mildly-reduced-cardiac-function-100617545","NCT07320014","Descriptive Study of Circulating Gene or Protein Inflammatory Biomarkers and Bioimpedance Parameters in a Population of Patients Hospitalized for Decompensated Heart Failure With Preserved or Mildly Reduced Cardiac Function","Inflammatory Profile in Patients Hospitalized for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Its Correlation With Bioimpedance Parameters and Other Biomarkers With Prognostic Value","BIOFEVIP","Inclusion Criteria:\n\n* Age ≥18 years at recruitment.\n* Signed informed consent.\n* Hospitalization due to decompensated heart failure, based on Framingham criteria and elevated natriuretic peptides (N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) ≥450 pg\u002Fml, or ≥900 pg\u002Fml for patients with atrial fibrillation or flutter).\n* Left ventricular ejection fraction(LVEF) ≥40% and evidence of structural heart disease based on the presence of at least one of the following imaging criteria:\n\n  * Left atrial dilation: LA diameter ≥3.8 cm, or area ≥20 cm², or LA volume ≥55 ml, or indexed LA volume ≥29 ml\u002Fm².\n  * Left ventricular hypertrophy, defined as septal or posterior wall thickness ≥1.1 cm.\n  * Evidence of increased filling pressures, measured by septal or lateral E\u002Fe' ratio \\>15 or \\>12, respectively.\n\nExclusion Criteria:\n\n* Hemodynamic instability at the time of inclusion.\n* Heart failure secondary to acute myocardial infarction (AMI).\n* Pregnant or breastfeeding women.\n* Comorbidities that could influence the clinical course:\n\n  * COPD requiring long-term home oxygen therapy, oral corticosteroids, hospitalization due to exacerbation, or primary pulmonary arterial hypertension.\n  * Chronic treatment with immunosuppressants, corticosteroids, or IL-1 antagonists within the 6 months prior to inclusion.\n  * Confirmed active infection or patients currently receiving antibiotic treatment.\n  * Acute or chronic liver disease.\n  * Chronic kidney disease with eGFR \\\u003C15 ml\u002Fmin\u002F1.73 m² or need for dialysis during hospitalization.\n  * Hematological disorders, such as blood dyscrasias or hemoglobin \\\u003C9 g\u002Fdl on admission.\n  * Active oncological disease, except treated basal cell carcinoma or low-risk prostate cancer.\n  * Patients with limb amputation or carriers of pacemakers or defibrillators (due to possible errors in BIA measurements).\n  * Any disease associated with a life expectancy of less than one year, or patients expected to have difficulty adhering to the study protocol\n* Patients actively participating in other clinical trials involving investigational drugs at the time of inclusion.",{"count":331,"type":23},112,"6 Months","The goal of this observational study is to determine whether changes in the inflammatory profile of heart failure patients can help identify those who may have a worse prognosis or who might benefit more from specific treatments. In addition, we aim to explore whether certain genes or gene mutations are related to a higher risk of future cardiovascular problems.\n\nHeart failure continues to be a major cause of hospital admissions and death in our society. Because of this, it is very important for healthcare professionals to identify which patients are at higher risk of complications, so that we can provide the best possible treatment and follow-up. One method we use to help predict how the disease may evolve is the study of biomarkers, which are measurable biological substances that can help detect, monitor, or treat illnesses in a more personalized way.\n\nIn this study, the investigators will measure mainly inflammatory biomarkers that will be analyzed from a blood sample taken during hospital stay after being diagnosed with heart failure with preserved or mildly reduced ejection fraction. Any important health events that happen during the next six months after patients are discharged from hospital will also be recorded.\n\nIn addition, it is known that more than 2,000 diseases are known to be caused by changes in specific genes. In the case of cardiomyopathies-heart muscle diseases that can lead to heart failure-genetic causes vary depending on the type, and studies suggest that between 10% and 50% of cases may have a genetic origin. Identifying genetic markers linked to heart failure with preserved or mildly reduced ejection fraction may help improve prevention, treatment, and risk assessment, as some genetic changes may be associated with repeated cardiovascular events. By studying not only circulating biomarkers but also genetic factors, the investigators hope to better understand whether certain gene alterations may increase a person's tendency to experience additional heart-related events.\n\nThis is an observational study, which means that medical care and treatment will be exactly the same whether patients choose to participate or not. Participation involves allowing researchers to collect relevant information from medical records and agreeing to the collection of two or three small additional blood samples for research purposes. These samples will be used to measure the biomarkers and to analyze genes in the white blood cell fraction obtained from the same tubes.",[29,173],[336,337,338,339],"inflammatory profile","heart failure with preserved ejection fraction","heart failure with mildly reduced ejection fraction","bioimpedance","2025-12-20",{"date":342,"type":45},"2026-01-06",{"date":344,"type":23},"2026-01",{"date":346,"type":23},"2028-01",{"name":348,"class":85},"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz",{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":24,"phases":358,"briefSummary":359,"conditions":360,"keywords":368,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":53},"100602469","studies-on-adsorption-international-learning-initiative-global-100602469","NCT07123909","Studies on Adsorption International Learning Initiative Global","The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome","SAILING","Inclusion Criteria:\n\n1. Adequate dialysis defined by a KT\u002FV index ≥ 1.4\n2. No active inflammatory process or infection\n3. Age ≥ 18 years\n4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session\n5. Participants with elevated interleukin-6 (IL-6) and\u002For C-reactive protein (CRP) levels exceeding local laboratory reference values\n\nExclusion Criteria:\n\n1. Current use of steroids or immunosuppressive therapy\n2. History of kidney transplantation\n3. Diagnosis of cancer\n4. Pregnancy",{"count":63,"type":23},[26],"Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia",[361,362,363,364,365,29,366,367],"CKD (Chronic Kidney Disease) Stage 5D","Uremia; Chronic","Uremic; Toxemia","Inflammation Chronic","Hemodialysis","Dialysis Related Complication","Anemia Associated With End Stage Renal Disease",[369,370,371],"Program dialysis","Sorption","Complications of program dialysis","2025-12-03",{"date":374,"type":45},"2025-12-10",{"date":376,"type":45},"2025-06-01",{"date":378,"type":23},"2026-06-30",{"name":380,"class":85},"Botkin Hospital",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":24,"phases":392,"briefSummary":393,"conditions":394,"keywords":404,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":53},"100599273","feasibility-and-potential-efficacy-of-herbs-and-spices-for-improving-dietary-quality-in-college-students-a-pilot-study-100599273","NCT07082348","Feasibility and Potential Efficacy of Herbs and Spices for Improving Dietary Quality in College Students: A Pilot Study","Assessing the Feasibility and Potential Efficacy of Herbs and Spices for Improving Dietary Quality and Adherence to the Dietary Guidelines for Americans in College Students With Poor Dietary Quality: A Pilot Study","HerbSpicesDiet","Inclusion Criteria:\n\n* College students (undergraduate and graduate)\n* Ages 18-39 years\n* BMI 18.5-40 kg\u002Fm\n* Having poor dietary quality (a Rapid Prime Diet Quality Score of 12 or below),\n* Maintain current lifestyle habits (e.g., medications\u002F supplement use, exercise, and sleep), and avoid taking new supplements or medications throughout the study.\n\nExclusion Criteria:\n\n* Individuals diagnosed with myocardial infarction within the past 6 months\n* Uncontrolled hypertension\n* BMIs \\\u003C18.5 or \\>40 kg\u002Fm2\n* Autoimmune disease or immune compromised\n* A recent diagnosis of cancer or under current treatment for cancer\n* A history of kidney stones\n* Having pacemaker\n* Participating in a weight loss program\n* Having a history of any significant GI disease\n* Insulin use\n* Currently on dialysis\n* Currently consuming pro-\u002Fpre-biotics or antiobiotics\n* Diagnosed with unstable chronic metabolic disease\n* Have allergies to any herbs and spices\n* Are pregnant\u002Fnursing\n* Participating in another investigational study\n* Unable or unwilling to give consent","39 Years",{"count":391,"type":23},30,[26],"The goal of this single-arm feasibility, pilot study is to assess the feasibility, acceptability, and potential effectiveness of the Herbs and Spices Nutrition Education Program (HSNP-focusing on incorporating herbs and spices into the diet for adherence to the DGA's) for determining the scalability of implementing this intervention for a larger scale, more comprehensive study The main questions it aims to answer are:\n\n* What is the feasibility and acceptability of incorporating herbs and spices into the diet along with DGA-focused nutrition education through the HSNP in college students with poor dietary quality?\n* What are the preliminary effects of the HSNP on dietary intake\u002Fquality, cardiometabolic, and gut health in college students with poor dietary quality?\n* What are the barriers associated with HSNP implementation in college students with poor dietary quality?\n\nParticipants will:\n\n* Be asked to come to the study site initially for a Screening Study Visit to confirm eligibility.\n* Be asked to come the clinical study site for a Pre-HSNP and Post-HSNP Study Visit (one week prior starting the HSNP and after week 6 of completing the HSNP) for assessments of cardiometabolic and gut health.\n* Be asked to come to the Nutrition Center for weeks 0 and 3 of the HSNP, where they will receive education on the Dietary Guidelines for Americans and the health benefits of herbs and spices, have a sensory evaluation of foods, be provided budget-friendly recipes and resources, and given take-home herbs, spices, and supporting materials\n* Be asked to complete 3-Day Food Records throughout the 6 week study period for assessment of dietary quality (4 total)",[395,396,397,398,399,400,401,402,29,258,403],"Dietary Quality","Feasibility Studies","College Student","Dietary Guidelines for Americans","Gut Microbiome","Lipid Profiles","Herbs and Spices","Acceptability","Anthropometrics",[405,406,407,39,408],"dietary quality","dietary guidelines for americans","college students","gut microbiome","2025-11-18",{"date":411,"type":45},"2025-11-24",{"date":413,"type":45},"2025-07-03",{"date":415,"type":23},"2026-12-31",{"name":417,"class":85},"University of Nevada, Las Vegas",{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":18,"minAge":426,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":438,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":448,"locationsCount":449},"100578896","how-a-mediterranean-diet-with-potatoes-impacts-heart-and-metabolic-health-in-adults-with-pre-diabetes-100578896","NCT06817252","How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes","Effects of a Mediterranean Dietary Pattern With White Potato on Cardiometabolic Health in Adults With Pre-Diabetes","MEDPOT-PREDM","Inclusion Criteria:\n\n* Men and postmenopausal women within the Las Vegas\u002FHenderson NV area\n* Ages 45-80 years\n* BMI between 25-40 kg\u002Fm2\n* HbA1c between 5.7-6.4%\n* Individuals from different demographic backgrounds (i.e., American Indian or Alaska Native, Caucasians, Asian, Black or African-American, Native Hawaiian, Hispanic, Latino or Pacific Islander)\n* Individuals who are considered \"non-frequent\" white potato consumers (\\\u003C2 servings of baked potatoes\u002Fweek)\n* Individuals from all races, genders, sexual identities, and religions will be included\n* Individuals must follow certain guidelines, including avoiding new medications during the study or significant changes to lifestyle factors (e.g. beginning to smoke or exercise more or less than usual)\n\nExclusion Criteria:\n\n* Individuals with uncontrolled hypertension (≥160\u002F100mmHg), active cancer, asthma, thyroid, kidney, liver, or pancreatic diseases\n* Individuals who are currently using insulin, on dialysis, changing\u002Fadding hypoglycemic, anti-hypertensive, and hypocholesterolemic medication within ≤3 months (or throughout the study)\n* Individuals participating in weight loss programs or another clinical trial\n* Individuals who start smoking\n* Individuals who have unstable metabolic or chronic diseases\n* Individuals who may have allergies to potatoes\n* Woman who are currently pregnant, think they may be pregnant, or who is nursing cannot participate (women must be postmenopausal)","45 Years","80 Years",{"count":63,"type":23},[26],"The goal of this clinical trial is to is to determine the effects of baked potato with the skin (BP) + nutrition education focused on adherence for a Mediterranean Dietary Pattern (MEDNE) on glycemic control, cardiometabolic health, and dietary quality in individuals with pre-diabetes from different demographic backgrounds. The main questions it aims to answer are:\n\n* Does BP+MEDNE contribute to improvements in indices of glycemic control, vascular function, blood lipids, inflammation\u002Foxidative stress, and body composition?\n* Does BP+MEDNE contribute to improvements to overall dietary intake and quality?\n\nResearchers will compare BP+MEDNE to MEDNE alone to see if BP+MEDNE can improve glycemic control, cardiometabolic health, and dietary quality in individuals with pre-diabetes from different demographic backgrounds.\n\nParticipants will:\n\n* Be asked to come to the study site initially for a Screening Study Visit to confirm eligibility.\n* Be asked to come the study site for a Pre-Baseline and Pre-12-Week Study Visit (one week prior to Baseline and 12-Week Study Visits) for placement of placement of a continuous glucose monitor and wearable devices to be removed at Baseline and 12-Week Study Visits.\n* Be asked to come to the study site for Baseline, 6- and 12-Week Study Visits for assessments of glycemic control and cardiometabolic health.\n* Be asked to complete 3-Day Food Records throughout the 12 week study period for assessment of dietary quality (5 total)\n* Receive pre-recorded MEDNE ( which can be accessed via computer device\u002Fipad\u002Fsmartphone) after Baseline and 6-Week Study Visits.\n* If randomized to the BP+MEDNE group, participants will receive pre-prepared baked potatoes with the skin for the 12-week study period (every 3 weeks) at Baseline and 6-Week Study Visits and asked to come to the study site for picking up the pre-prepared baked potatoes at weeks 3 and 9 of the study period.",[432,176,433,434,170,29,395,435,436,437],"Prediabetes","Hypertension","Glycemic Control","Body Composition Measurement","Waist Circumference","Anthropometrics: Height and Weight",[439,432,440,441,395],"White Potato","Mediterranean Diet","Cardiometabolic Health","2025-11-17",{"date":444,"type":45},"2025-11-20",{"date":446,"type":45},"2025-04-24",{"date":415,"type":23},{"name":417,"class":85},2,{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":18,"minAge":457,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":24,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":53},"100579735","dietary-wild-blueberries-and-joint-health-100579735","NCT06828159","Dietary Wild Blueberries and Joint Health","Effects of Dietary Wild Blueberries on Gut Health and Inflammation and Joint Pain","Inclusion Criteria:\n\n* Adults with documented multi-joint\u002Fknee arthritis\n\nExclusion Criteria:\n\n* inability to give informed consent\n* pregnancy or lactation\n* planned knee replacement surgery\n* allergy or contraindication to berries\n* recent trauma of the knee responsible of the symptomatic knee\n* intra-articular injection in the target knee\u002Fhip in the last 3 months\n* oral corticosteroid therapy ≥ 5 mg\u002Fday (prednisone equivalent) at baseline\n* use of berry extracts in the last 3 months\n* special diets\n* cancer treatment\n* bone diseases","40 Years","75 Years",{"count":135,"type":23},[26],"The goal of this proposed study is to examine the effects of dietary wild blueberries on gut microbiome, serum markers of inflammation, and joint function in adults. Each participant will consume 25g freeze-dried blueberries or matched placebo powder for 12 weeks, with a 2-week washout phase between.",[463,29,464,465],"Gut -Microbiota","Pain Assessment","Joint Pain","2025-11-03",{"date":468,"type":45},"2025-11-05",{"date":470,"type":45},"2025-09-01",{"date":472,"type":23},"2028-03",{"name":417,"class":85},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":482,"enrollmentInfo":483,"targetDuration":485,"studyType":64,"phases":4,"briefSummary":486,"conditions":487,"keywords":493,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":53},"100594996","tirana-acs-a-prospective-registry-study-for-the-targeted-investigation-of-residual-inflammation-after-non-st-st-elevation-acute-coronary-syndrome-100594996","NCT07026708","TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST\u002F ST Elevation Acute Coronary Syndrome","Target Investigation of Residual Inflammation After Non-ST\u002F ST Elevation Acute Coronary Syndrome - TIRANA (ACS) Prospective REGISTRY","TIRANA (ACS)","Inclusion Criteria:\n\n\\- All patients (undergoing PCI, aged 18-85 years) presenting to the cardiology department or\u002Fand the cardiology intensive care unit with a diagnosis of ACS\n\nExclusion Criteria:\n\n* Patients presenting to the cardiology department or\u002Fand the cardiology intensive care unit with diagnoses other than ACS and\u002For UA. Patients who died before undergoing PCI and those who did not provide a contact number.","85 Years",{"count":484,"type":23},1600,"2 Years","This prospective observational study aims to evaluate the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) as a predictor of mortality in patients following an episode of Acute Coronary Syndrome (ACS). Despite advancements in interventional cardiology and medical therapy, mortality remains significant in post-ACS patients, and early risk stratification is essential for optimizing outcomes.\n\nRecent studies have suggested that systemic inflammatory markers, such as NLR, are associated with adverse cardiovascular events. It is an easily obtainable and cost-effective laboratory parameter derived from a routine complete blood count. However, its value as an independent predictor of mortality post-ACS has not yet been fully established in our population.\n\nThe study will include patients aged, admitted with a confirmed diagnosis of ACS (STEMI or Non-STEMI) and treated with percutaneous coronary intervention (PCI). NLR values will be measured from the first blood draw upon hospital admission, 24 and 48 hours post PCI. Patients will be followed up for up to 6 months after discharge through telephone interviews .\n\nFirst, primary outcomes of the study will be the association between NLR values and mortality (all cause mortality and cardiovascular mortality), MACE (MACE was defined as the composite of all-cause mortality, cardiac death, unplanned revascularization, non-fatal myocardial infarction that was attributable and not related to stent failure or unplanned revascularization not related to stent failure) within 6 months post-ACS.\n\nSecondary outcomes will include:\n\n1. Differences in mean NLR between STEMI and NSTEMI patients.\n2. Association between elevated NLR and the presence of multivessel coronary artery disease on angiography.\n3. Correlation of NLR with other biomarkers, including the platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, and maximum troponin levels (as an indicator of myocardial infarction size)\n\nThis study aims to contribute to the identification of easily accessible and cost-efficient biomarkers that can aid clinicians in early risk stratification of ACS survivors. A strong correlation between high NLR values and increased post-discharge mortality would suggest that inflammation plays a key role in patient prognosis and could potentially influence post-ACS management strategies.",[488,489,490,29,491,492],"ACS (Acute Coronary Syndrome)","Myocardial Infarction (MI)","Myocardial Inflammation","NSTEMI - Non-ST Segment Elevation MI","STEMI",[494,495,496,497],"Residual inflammation","Myocardial infarction","Percutaneous Coronary Intervention","Acute Coronary Syndrome","2025-09-27",{"date":500,"type":45},"2025-09-30",{"date":502,"type":45},"2024-11-01",{"date":504,"type":23},"2027-06-01",{"name":506,"class":85},"University Hospital Centre Mother Teresa",{"id":508,"slug":509,"hasResults":11,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":426,"enrollmentInfo":515,"targetDuration":4,"studyType":24,"phases":517,"briefSummary":519,"conditions":520,"keywords":526,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":538,"locationsCount":53},"100602019","phase-2-effects-of-adjunct-omega-3-long-chain-polyunsaturated-fatty-acids-in-pulmonary-tuberculosis-patient-an-early-bactericidal-activity-and-inflammatory-trial-100602019","NCT07118059","Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial","Effects of Adjunct Omega-3 Long-chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patients: An Early Bactericidal Activity and Inflammatory Activity Trial","TREAT 3","Inclusion Criteria:\n\n* adults aged 18-45 years\n* laboratory confirmed Pulmonary TB defined as a hard copy of a sputum result detected by WHO recommended assay or mycobacteria culture.\n* Women of childbearing potential with a negative pregnancy test on enrollment\n* All participant irrespective of HIV status who consent to have a HIV test during enrollment.\n\nExclusion Criteria:\n\n* Comorbid condition with treatment of NSAIDS is indicated\n* Institutionalized or incarcerated individuals\n* Those on Multiple drug resistance treatment for more than 4 days within the past 6 months or within 1 month to prior to TB treatment initiation\n* Pregnant or breastfeeding women or women who become pregnant in the first 4 weeks of the trial will be withdrawn\n* show lab safety values: AST or ALT \\> x3 upper limit of normal (ULN) or Total bilirubin \\> 2x the ULN, Neutrophils ≤ 700\u002Fmm³, Platelets \\\u003C 50,000\u002Fmm³, Haemoglobin \\\u003C 8 g\u002FdL, Serum creatinine \\> 2× ULN.\n* Are receiving or planning treatment with any of the following in the 3 months before or during the trial:\n\nAnticoagulants Immune-modulating therapy (e.g., cancer treatment, oral\u002Finhaled corticosteroids) Antacids or proton pump inhibitors (PPIs)\n\n* Have a known allergy or sensitivity to fish or fish oil.\n* Have a recent history (within 2 years) or current clinical evidence of:\n\nPeptic ulcer disease or GI bleeding Coagulopathy or bleeding disorders Kidney or liver disease requiring hospitalisation Cardiovascular disease or significant risk factors for it\n\n-Are HIV-positive and meet any of the following: CD4 count \\\u003C 100 cells\u002Fmm³ Viral load \\> 400 copies\u002FmL (if on ART) Not yet on ART but are expected to initiate treatment during the 8-week intervention phase\n\n* Report high-risk alcohol use (average \\>4 units\u002Fday or binge drinking patterns)\n* Have any other medical condition or situation that, in the investigator's opinion, may interfere with protocol adherence or data interpretation.\n* Plan to relocate from the study area within the next 3 months.\n* Are currently using omega-3 or omega-6 supplements and are unwilling to stop for the duration of the study.",{"count":516,"type":23},40,[518],"PHASE2","The goal of this randomized controlled trial is to evaluate the early bactericidal activity, early inflammatory response, and safety of omega-3 long chain polyunsaturated fatty acid (n-3 PUFA) supplementation in adult patients (aged 18- 45 years) with newly diagnosed, bacteriologically confirmed drug-sensitive pulmonary tuberculosis.\n\nThe main questions it aims to answers are:\n\n* Does adjunct n-3 LCPUFA supplementation reduce the sputum culture time to positivity\n* Does it improve inflammatory markers and TB treatment outcomes compared to placebo Researchers will compare daily supplementation with \\~2g n-3 LCPUFA (EPA and DHA ) to placebo (high linoleic sunflower oil) to determine effects on bactericidal activity, inflammation, and clinical outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either n-3 LCPUFA or Placebo daily for 8 weeks with the intensive phase of TB treatment\n* Attend clinical visit baseline, and follow up visit mostly weekly for 2 months and then monthly for 4 months of the continuous phase of TB treatment\n* Provide blood, sputum and urine samples for biomarkers and metabolomic analysis\n* Undergo assessments of iron status, body composition and muscle strength",[521,29,522,523,275,524,525],"Tuberculosis","Liver Function Tests","Iron Status","Nutritional Status","Clinical Outcomes",[527,528,529,530,531],"Pulmonary tuberculosis","Patients","adjunct omega-3 long chain polyunsaturated fatty acid","early bactericidal","safety trial","2025-08-04",{"date":534,"type":45},"2025-08-12",{"date":536,"type":23},"2025-08",{"date":152,"type":23},{"name":539,"class":85},"North-West University, South Africa",{"id":541,"slug":542,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":17,"sex":18,"minAge":546,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":24,"phases":549,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":53},"100588511","effect-of-walnuts-on-cognitive-function-and-gut-microbiome-in-older-adults-100588511","NCT06942351","Effect of Walnuts on Cognitive Function and Gut Microbiome in Older Adults","Inclusion Criteria:\n\n* Age 55 years or older\n* Able to hear well enough to understand spoken instructions and questions\n* Able to see well enough to read and respond to printed instructions and fill out questionnaires (corrective lenses are allowed)\n* Able to write legibly and move a computer joystick with at least one hand (i.e., no injury or connective tissue or joint disorder that would impair ability to write or make hand movements)\n* Able to speak, read, and understand English\n* Score of greater than 79 on water maze learning task\n* Willing to maintain current eating patterns\n* Willing and able to complete the cognitive tests\n* Willing to stop consuming almonds, Brazil nuts, cashews, chestnuts, hazelnuts, macadamia nuts, peanuts, pecans, pistachios, walnuts, persimmons and pomegranates for 14 weeks. - are nuts or contain ellagitannins or ellagic acid - compounds\u002Ffoods of interest for this study\n* Willing to limit oak aged wines and spirits to 1 serving\u002Fday and limit blackberries (including similar berries like boysenberries, marionberries, and olallieberries), cloudberries, cranberries, currants, elderberries, lingonberries, raspberries, strawberries, wolfberries, other native berries; guava, mango, muscadine grapes, nectarines, peaches, plums, pluots to 1 cup\u002Fday for 14 weeks; REMAIN CONSISTENT (consistent intake levels of): Coffee, tea, apple, apricots, blueberries, cherries, grapes (table\u002Fcommon)\n* Willing to stop probiotic supplements 2 weeks prior to and during the study (14 weeks)\n\nExclusion Criteria:\n\n* Consumption of walnuts, pecans, and chestnuts combined greater than 2 oz \u002F week in the past 3 months.\n* Use of oral antibiotics in the past month\n* Regular use of oral anti-inflammatory medications in the past month\n* Nut, wheat, or gluten allergy\u002Fintolerance\n* Pregnant or planning to become pregnant during the study period\n* Weighs less than 110 pounds\n* Diagnosis of sickle cell disease\n* Susceptibility to motion sickness\n* Consumes 3 or more alcoholic drinks daily\n* History of smoking tobacco products, including e-cigarettes and vaporizers in the past 2 years (smokeless tobacco use not exclusionary)\n* Use of psilocybin or cannabis products (including CBD-only products) in the past 2 years\n* Current treatment for alcohol or other substance use disorder\n* History of heart attack, heart failure, or stroke, including transient ischemic attack\n* History of liver disease or kidney disease requiring dialysis\n* History of cancer in the past 5 years (Skin cancer that was only surgically treated is not exclusionary)\n* History of bariatric surgery (e.g., gastric bypass, gastric banding, sleeve gastrectomy, etc.) or disorders (e.g., Crohn's disease, unmanaged celiac disease, ulcerative colitis)\n* History of thyroid disorder that requires medication, but subject is not taking medication\n* History of chronic bronchitis or emphysema\n* Diagnosis of dementia or Alzheimer's disease\n* History of head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* History of chronic migraines (for at least 3 months, headache occurring on 15 or more days per month, where at least 8 of those headache days have migraine symptoms)\n* Blood pressure above 159 (systolic) or 99 (diastolic) mm Hg\n* Corrected vision worse than 20\u002F50\n* Score of less than 10\u002F15 on Ishihara color vision test or diagnosis of color blindness\n* Score of less than 26\u002F30 on Mini-Mental State Exam\n* Score of greater than 15 on Center for Epidemiologic Depression survey\n* History of disease or disorder which causes cognitive impairment, including but limited to: attention-deficit\u002Fhyperactivity disorder (ADHD), amyotrophic lateral sclerosis, autism, bipolar disorder, Down's syndrome, encephalitis, epilepsy\u002Fseizures, human immunodeficiency virus (HIV), Huntington's disease, Korsakoff's psychosis, multiple sclerosis, Parkinson's disease, or psychotic disorders (e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder)\n* Current and regular use of any of the following medications: insulin, opioids, anti-seizure medications, psychotropic medications: stimulants, anti-psychotics, or medications that cause daytime drowsiness or difficulty concentrating","55 Years",{"count":548,"type":23},80,[26],"The purpose of this study is to examine the impact of daily consumption of walnuts for 12 weeks on cognitive function, markers of inflammation and oxidative stress, and the gut microbiome in healthy adults age 55 years and older.",[300,29],[408,553,554],"walnuts","cognitive function","2025-06-17",{"date":557,"type":45},"2025-06-19",{"date":559,"type":45},"2025-06-09",{"date":561,"type":23},"2029-05",{"name":563,"class":85},"Oregon State University",{"id":565,"slug":566,"hasResults":11,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":457,"enrollmentInfo":571,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":580,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":53},"100586172","the-effect-of-time-restricted-eating-on-glycemic-and-proinflammatory-biomarkers-among-prediabetic-obese-jordanian-adults-aged-18-40-years-old-100586172","NCT06911918","The Effect of Time Restricted Eating on Glycemic and Proinflammatory Biomarkers Among Prediabetic Obese Jordanian Adults Aged 18-40 Years Old","The Effect of Time Restricted Eating on Glycemic and Proinflammatory Biomarkers Among Prediabetic Obese Jordanian Adults Aged 18-40 Years Old: A Randomized Control Study","Inclusion Criteria:\n\n* IR individuals diagnosed with IR by the physicians as indicated by HOMA-IR score\n* female and male, BMI ≥ 30 to 39.9 kg\u002Fm2\n* age between 18 and 40 years\n* stable weight for 3 months before the beginning of the study\n* sedentary lifestyle\n\nExclusion Criteria:\n\n* previous weight loss surgery\n* pregnancy or intent to become pregnant\n* breastfeeding\n* chronic diseases\n* drug therapies that could interfere with the effectiveness of the dietary intervention (e.g., use of corticosteroids, and anti-diabetic drugs)\n* diabetic type 1 and 2 individuals\n* anyone physically active to reduce the influence of confounding covariates",{"count":572,"type":23},120,[26],"Obesity, a global epidemic, significantly contributes to prediabetes, cardiovascular diseases, and other chronic diseases due to its pro-inflammatory nature. This studyl investigates the effects of time-restricted eating (TRE) with calorie restriction (CR), TRE without CR, and CR without TRE on glycemic control and pro-inflammatory biomarkers among prediabetic obese Jordanian adults aged 18-40 years. The study assesses changes in pro-inflammatory biomarkers (IL-1β, TNF-α, IL-6), insulin resistance (HOMA-IR), and body composition over 12 weeks.\n\nParticipants (n=120) will be randomized into four intervention arms: (1) TRE with CR, (2) TRE without CR, (3) CR without TRE, and (4) a control group with no dietary restrictions and no TRE. Biweekly anthropometric assessments will evaluate pro-inflammatory biomarkers and biochemical measures at baseline and the end of the study. The findings will provide insights into the comparative effectiveness of TRE and CR, potentially offering a safe, cost-effective intervention to prevent obesity-induced inflammation, prediabetes, and progression to type 2 diabetes mellitus.",[576,29,577,578,579],"Insulin Resistance","Time Restricted Eating","Caloric Restriction","Obesity (Disorder)",[581,576,278,578,582],"Time restricted eating","Inflammation cytokines","2025-03-27",{"date":585,"type":45},"2025-04-04",{"date":587,"type":23},"2025-04-05",{"date":589,"type":23},"2025-11",{"name":591,"class":85},"University of Jordan"]